Profluent's $106M Bet on AI-Designed Proteins

Profluent, a pioneer in generative AI for protein design, has secured a $106 million venture round to propel its computationally engineered therapies toward human testing. The company leverages large language models trained on biological sequences to design novel, functional proteins from scratch, aiming to create new classes of therapeutics. The new capital will specifically fund IND-enabling studies and a first-in-human Phase 1 trial for PF-001, its lead in vivo gene editing candidate, alongside expansion of its protein generation platform. Spark Capital, a venture firm with a history of backing foundational tech companies, led the round, signaling strong institutional belief in the platform's potential. The financing underscores growing investor conviction that AI-driven generative biology can move beyond research tools to deliver clinical assets.